Anti-angiogenic activity of inositol hexaphosphate (IP6)

Carcinogenesis

Volumn 25, Issue 11, 2004, Pages 2115-2123

  Vucenik, Ivana ^a   Passaniti, Antonino ^a   Vitolo, Michele I ^a   Tantivejkul, Kwanchanit ^a,e   Eggleton, Paul ^b,c,d   Shamsuddin, AbulKalam M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CALRETICULIN; MATRIGEL; MESSENGER RNA; PHYTIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOSTATIN;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARCINOGENESIS; CATTLE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; CALRETICULIN; CATTLE; CELL DIVISION; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; PHYTIC ACID;

EID: 8844244745     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh232     Document Type: Article

References (72)

1. 6: a review. Anticancer Res., 18, 3733-3736.
2. 3H]-inositol hexakis-phosphate binding to rat cerebellar membranes. J. Biol. Chem. 268, 1032-1038.
3. Graf,E. and Eaton,J.W. (1990) Antioxidant functions of phytic acid. Free Radical Biol. Med., 8, 61-69.
4. Sasakawa,N., Sharif,M. and Hanley,M.R. (1995) Metabolism and biological activities of inositol pentakisphosphates and inositol hexakis-phosphate. Biochem. Pharmacol., 50, 137-146.
5. Shears,S.B. (1996) Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates: novel effects on ion channels and protein traffic. Sub-Cell. Biochem. 26, 187-226.
6. 2+-mediated exocytosis of insulin by activation of protein kinase C. Proc. Natl Acad. Sci. USA, 94, 4435-4439.
7. 2+ channel activity by inositol hexakisphosphate. Science, 278, 471-474.
8. York,J.D., Odom,A.R., Murphy,R., Ives,E.B. and Wente,S.R. (1999) A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science, 285, 96-100.
9. Odom,A.R., Stahlberg,A., Wente,S.R. and York,J.D. (2000) A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. Science, 287, 2026-2029.
10. 6: a novel anticancer agent. Life Sci., 61, 343-354.
11. Shamsuddin,A.M. (2002) Anti-cancer function of phytic acid. Int. J. Food Sci. Technol., 37, 769-782.
12. 6): from laboratory to clinic. J. Nutr., 133, 3778S-3784S.
13. 6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res., 16, 3287-3292.
14. Sakamoto,K., Venkatraman,G. and Shamsuddin,A.M. (1993) Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). Carcinogenesis, 14, 1815-1819.
15. Vucenik,I., Sakamoto,K., Bansal,M. and Shamsuddin,A.M. (1993) Inhibition of mammary carcinogenesis by inositol hexaphosphate (phytic acid). A pilot study. Cancer Lett., 75, 95-102.
16. Vucenik,I., Yang,G.-Y. and Shamsuddin,A.M. (1995) Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. Carcinogenesis, 16, 1055-1058.
17. 6) and high-bran diet in the prevention of DMBA-induced rat mammary carcinogenesis. Nutr. Cancer 28, 7-13.
18. 6: a review. Anticancer Res., 19, 3671-3674.
19. Shamsuddin,A.M. and Ullah,A. (1989) Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. Carcinogenesis, 10, 625-626.
20. Shamsuddin,A.M., Ullah,A. and Chakravarthy,A. (1989) Inositol and inositol hexaphosphate suppresses cell proliferation and tumor formation in CD-1 mice. Carcinogenesis, 10, 1461-1463.
21. Ullah,A. and Shamsuddin,A.M. (1990) Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344 rats. Carcinogenesis, 11, 2219-2222.
22. Pretlow,T.P., O'Riordan,M.A., Somich,G.A., Amini,S.B. and Pretlow,T.G. (1992) Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis, 13, 1509-1512.
23. Challa,A., Rao,D.R. and Reddy,B.S. (1997) Interactive suppression of aberrant crypt foci induced by azoxymethane in rat colon by phytic acid and green tea. Carcinogenesis, 18, 2023-2026.
24. Vucenik,I., Tomazic,V.J., Fabian,D. and Shamsuddin,A.M. (1992) Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. Cancer Lett., 65, 9-13.
25. Vucenik,I., Kalebic,T., Tantivejkul,K. and Shamsuddin,A.M. (1998) Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. Anticancer Res., 18, 1377-1384.
26. 6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res., 18, 4083-4090.
27. 6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res., 18, 4091-4096.
28. 6 or phytate) in humans. Biofactors, 15, 53-61.
29. 3H]-PhytiC acid (inositol hexaphosphate) is absorbed and distributed to various tissues in rats. J. Nutr., 123, 713-720.
30. Folkman,J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med., 1, 27-31.
31. Folkman,J. (1995) Clinical applications of research on angiogenesis. N. Engl. J. Med., 333, 1757-1763.
32. Griffioen,A.W. and Molema,G. (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol. Rev., 52, 237-268.
33. Folkman,J. (1986) How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res., 46, 467-473.
34. Cross,M.J. and Claesson-Welsh,L. (2001) FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci., 22, 201-207.
35. Rosen,L.S. (2001) Angiogenesis inhibition in solid tumor. Cancer J., 7 (suppl. 3), S120-S128.
36. D'Amato,R.J., Loughnan,M.S., Flynn,E. and Folkman,J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082-4085.
37. Motzer,R.J., Berg,W., Ginsberg,M., Russo,P., Vuky,J., Yu,R., Bacik,J. and Mazumdar,M. (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol., 20 302-306.
38. Steins,M.B., Padro,T., Bieker,R., Ruiz,S., Kropff,M., Kienast,J., Kessler,T., Buechner,T., Berdel,W.E. and Mesters,R.M. (2002) Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood, 99, 834-839.
39. Ingber,D., Fujita,T., Kishimoto,S., Sudo,K., Kanamaru,T., Brem,H. and Folkman,J. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature, 348, 555-557.
40. Moore,J.D., Dezube,B.J., Gill,P., Zhou,X.J., Acosta,E.P. and Sommadossi,J.P. (2000) Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Cancer Chemother. Pharmacol., 46, 173-179.
41. Cao,Y., Ji,R.W., Davidson,D., Schaller,J., Marti,D., Söhndel,S., McCance,S.G., O'Reilly,M.S., Llinás,M. and Folkman,J. (1996) Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem., 271, 29461-29467.
42. O'Reilly,M.S., Boehm,T., Shing,Y., Fukai,N., Vasios,G., Lane,W.S., Flynn,E., Birkhead,J.R., Olsen,B.R. and Folkman,J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285.
43. Jiang,C., Agarwal,R. and Lü,J. (2000) Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, sylmarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochem. Biophys. Res. Commun., 276, 371-378.
44. Kim,M.S., Lee,Y.M., Moon,E.-J., Kim,S.E., Lee,J.J. and Kim,K.-W. (2000) Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. Int. J. Cancer, 87, 269-275.
45. Jung,Y.D., Kim,M.S., Chay,K.O., Ahn,B.W., Liu,W., Bucana,C.D., Gallick,G.E. and Ellis,L.M. (2001) EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br. J. Cancer, 84, 844-850.
46. Pike,S.E., Yao,L., Jones,K.D. et al. (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med., 188, 2349-2356.
47. Pike,S.E., Yao,L., Setsuda,J. et al. (1999) Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood, 94, 2461-2468.
48. Yao,L., Pike,S.E., Setsda,J., Parekh,J., Gupta,G., Raffeld,M., Jaffe,E.S. and Tosato,G. (2000) Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood, 96, 1900-1905.
49. Yang,J., Nagavarapu,U., Relloma,K., Sjaastad,M.D., Moss,W.C., Passaniti,A. and Herron,G.S. (2001) Telomerized human microvasculature is functional in vivo. Nat. Biotechnol., 19, 219-224.
50. Kishore,U., Sontheimer,R.D., Sastry,K.N., Zaner,K.S., Zappi,E.G., Hughes,G.R., Khamashta,M.A., Strong,P., Reid,K.B. and Eggleton,P. (1997) Release of calreticulin from neutrophils may alter C1q-mediated immune functions. Biochem. J., 322, 543-550.
51. Pili,R., Chang,J., Partis,R.A., Mueller,R.A., Novick,T., Chrest,F.J. and Passaniti,A. (1995) The α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis and inhibits tumor growth. Cancer Res., 55, 2920-2926.
52. Passaniti,A., Taylor,R.M., Pili,R., Guo,Y., Long,P.V., Haney,J.A., Pauly,R.R., Grant,D.S. and Martin,G.R. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab. Invest., 67, 519-528.
53. Burchardt,M., Burchardt,T., Chen,M.-W., Shabsigh,A., de la Taille,A., Buttyan,R. and Shagsigh,R. (1999) Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans. Biol. Reproduct., 60, 398-404.
54. Chou,T.-C. and Talalay,P. (1987) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27-55.
55. 6) inhibits key events of cancer metastasis: In vitro studies of adhesion, migration and invasion of MDA-MB 231 human breast cancer cells. Anticancer Res., 23, 3671-3680.
56. 6). Anticancer Res., 21 2393-2404.
57. 2+ and protein kinase C signaling pathway in HepG2 human hepatoblastoma cells. Int. J. Mol. Med., 7, 91-96.
58. Tossetti,F., Ferrari,N., De Flora,S. and Albini,A. (2002) Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agent. FASEB J., 16, 2-14.
59. Singh,R.P., Agarwal,C. and Agarwal,R. (2003) Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of prostate carcinoma DU145: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis, 24, 555-563.
60. Singh,R.P., Sharma,G., Mallikarjuna,G.U., Dhanalakshmi,S., Agarwal,C. and Agarwal,R. (2004) In vivo suppression of hormone-refractory prostate cancer growth by inositol heaxaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin. Cancer Res., 10, 244-250.
61. 6): an antagonist of fibroblast growth factor receptor binding and activity. In vitro Cell. Dev. Biol., 30A, 783-789.
62. Torimura,T., Sata,M., Ueno,T., Kin,M., Tsuji,R., Suzaku,K., Hashimoto,O., Sugawara,H. and Tanikawa,K. (1998) Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum. Pathol., 29, 986-991.
63. Tokunaga,T., Oshika,Y., Abe,Y. et al. (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer, 77, 998-1002.
64. Blancher,C., Moore,J.W., Robertson,N. and Harris,A.L. (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1a, HIF-2a and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res., 61, 7349-7355.
65. Milanini,J., Vinals,F., Pouyssegur,J. and Pages,G. (1998) p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblast. J Biol. Chem., 273, 18165-18172.
66. Jung,Y.D., Nakano,K., Liu,W., Gallick,G.E. and Ellis,L.M. (1999) Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cell. Cancer Res., 59, 4804-4807.
67. Huang,C., Ma,W.-Y., Hecht,S.S. and Dong,Z. (1977) Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase. Cancer Res. 57, 2873-2878.
68. Zi,X., Singh,R.P. and Agarwal,R. (2000) Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis, 21, 2225-2235.
69. Ferry,S., Matsuda,M., Yoshida,H. and Hirata,M. (2002) Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFκB-mediated cell survival pathway. Carcinogenesis, 23, 2031-2041.
70. Vihinen,P. and Kahari,V.M. (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99, 157-166.
71. 6) and insulin-like growth factor II receptor binding sites in the rat brain. Neuroreport, 5, 625-628.
72. Kim,K.W., Bae,S.K., Lee,O.K., Bae,M.H., Lee,M.J. and Park,B.C. (1998) Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res., 58, 348-351.